🧬 New #EndometrialCancer educational video Prof. Christian Marth explores the latest treatment strategies for advanced/recurrent endometrial cancer 📺 Watch the animated video below to hear about: - Molecular subtypes in guiding treatment decisions - Current 1st line options in patients with non-dMMR advanced/recurrent EC, including immunotherapy, PARP inhibitors, and tyrosine kinase inhibitors Find out more about this programme & download the accompanying slides 👉 This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #MedEd #Oncology #GynecologicCancer

RT @PresOnc_Connect: 📢Save the date! HER2 testing: The evolving role of immunohistochemistry - best practices + interpretation of results…

RT @PresOnc_Connect: Don’t miss this interactive webinar on 11th March! 👉 The evolving role of immunohistochemistry in HER2 testing, best…

🧬Current treatment options in advanced/recurrent #endometrialcancer Explore the impact of molecular subtypes with Prof. Christian Marth 👇 A #MedEd programme with animated video & slides: This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #OncTwitter #GynecologicCancer

Is LEN/PEMBRO an optimal 1st line therapy option for non-dMMR advanced/recurrent EC? What about ICI + ChT? Which agents have shown efficacy, and how does PARPi maintenance therapy impact outcomes? Prof. Marth explains more in this #MedEd animated video & slides ➡️ This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #GynecologicCancer #EndometrialCancer

🧬 In #EndometrialCancer, molecular classification is crucial not only for prognosis but also for guiding personalised treatment decisions Prof. Christian Marth explores the latest treatment strategies for advanced/recurrent endometrial cancer ⬇️ He discusses: - Molecular subtypes in guiding treatment decisions - Current 1st line options in patients with non-dMMR advanced/recurrent EC, including immunotherapy, PARP inhibitors, and tyrosine kinase inhibitors 📺 Watch the animated video below Find out more about this programme & download the accompanying slides 👉 This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme. #MedEd #Oncology #GynecologicCancer

The @COR2EDMedEd YouTube account now has over 3000 subscribers! 🎉 Go and check it out 👇 #MedEd

❓ Are your patients anxious about #IUD placement? We have a podcast with #OBGyn experts who reveal essential strategies for managing anxiety and pain. Discover: ◾Misconceptions debunked ◾Reassurance techniques ◾Effective pain relief options 👉 #MedEd

🔥#ESMO2024 I ABS714MO 📊Dato-DXd results are in! For #EC patients: 27.5% ORR (1 CR, 10 PR), 85% DCR, and median PFS of 6.3 mos. For #OCpatients: 42.9% ORR (1 CR, 14 PR), 91.4% DCR, and median PFS of 5.8 mos. Both cohorts show strong efficacy! #MedEd

🔥#ESMO2024 I LBA33 ICON9 results: Olaparib + cediranib (O+C) showed a median PFS of 13.9 mos vs. 11.0 mos with O alone (HR=0.84, p=0.24). In tBRCA wt, PFS HR=0.77, OS HR=0.95. O+C had more grade ≥3 AEs (60.7% vs. 36.6%). O+C provided 1.9 mos more PFS in 24 mos. #MedEd

🔥📊#ESMO2024 I LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21 update: In high-risk #EC, pembro + CTx vs. pbo + CTx showed similar 2-year DFS (75% vs. 76%, HR 1.02). Pembro improved DFS in dMMR tumours (HR 0.31). Grade ≥3 AEs were 71% (pembro) vs. 63% (pbo). No grade 5 AEs. #MedEd

🔥📊#ESMO2024 I LBA29 #PRIMA trial: Niraparib (nir) vs. placebo (PBO) showed similar OS (HR 1.01). In HRd tumors, nir improved 5-year PFS (35% vs. 16% PBO). Lower subsequent PARPi therapy with nir (11.7% vs. 37.8% PBO). MDS/AML rates <2.5%. No new safety signals. #MedEd

🔥📊#ESMO2024 I LBA30 ATHENA COMBO trial: RUCA + NIVO showed shorter median PFS vs RUCA + PBO (15.0 vs 20.2 months; HR 1.3). RUCA alone maintained a PFS benefit. Common grade ≥3 AEs with COMBO were anemia (27.1%), neutropenia (25.4%), and liver enzyme increases (21.2%). #MedEd

📊 BRCA & #EC During 6.7 yrs of follow-up, 38 cases were found—mostly in BRCA1 carriers (3.4% incidence vs. 1.6% for BRCA2). Prior tamoxifen use doubled the risk (HR = 2.24). No significant links with hormone use, oophorectomy, smoking, or BMI. #MedEd

💡Interested in the latest in #PPH management? In our final podcast episode, Prof. Nándor Ács and Dr. Anne-Sophie Ducloy-Bouthors explore a decade of advancements, from new drugs to the WHO roadmap to combat PPH. Tune in for their insights!

🎙️Curious about PPH treatment options? In Part 3 of our #PPH podcast, Prof. Loïc Sentilhes & Prof. Christian von Heymann discuss strategies like tranexamic acid, blood transfusion timing, & the power of multidisciplinary collaboration. Don’t miss it!

🎙️ How can teamwork improve #PostPartumHaemorrhage management? Find out in Part 2 of our PPH podcast series with Prof. Andra H. James and Dr. Maria Elisa Mancuso as they discuss real cases and the power of cross-specialty collaboration. #MedEd

❓ Did you know that 14M women experience #PPH each year, with 70K maternal deaths? Listen to Drs Ahmadzia & Zdanowicz discuss this critical issue in our podcast series. 🩸Don't miss their insights on defining severe PPH, global differences, & more!

📊 New study on advanced #ovariancancer: 1L MT showed median TTD of 13.6 mos and rwPFS of 26.9 mos vs. 11.3 mos for AS (p < 0.0001). OS at 36 mos: 82.4% with MT vs. 58.0% with AS. Low genetic testing rates highlight need for improvement. #MedEd

🌸 Help raise awareness of womb cancer! @WombCancerUK is placing informative leaflets in GP surgeries to educate and empower women about symptoms, risk factors, and early detection. Together, we can make a difference in women's health. #MedEd